Detalles de la búsqueda
1.
Cost-Utility and Budget Impact Analyses of Oral Chemotherapy for Stage III Colorectal Cancer: Real-World Evidence after Policy Implementation in Thailand.
Cancers (Basel);
15(20)2023 Oct 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37894297
2.
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.
J Clin Oncol;
41(11): 1986-1991, 2023 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36306479
3.
Autoantibody profiles and clinical association in Thai patients with autoimmune retinopathy.
Sci Rep;
11(1): 15047, 2021 07 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34294798
4.
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
Clin Colorectal Cancer;
18(3): 183-191.e3, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31221542
5.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Lancet;
393(10183): 1819-1830, 2019 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30955977
6.
Efficacy and tolerability of BP-C1 in metastatic breast cancer: a Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study.
Breast Cancer (Dove Med Press);
11: 43-51, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30666153
7.
Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer.
PLoS One;
13(12): e0209040, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30566471
8.
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.
Lung Cancer;
126: 1-8, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30527172
9.
Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.
JAMA Oncol;
4(7): 977-984, 2018 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29566104
10.
Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study.
Support Care Cancer;
25(2): 459-464, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27714530
11.
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
Clin Colorectal Cancer;
16(2): e73-e88, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27780749
12.
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.
Lung Cancer;
98: 1-8, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27393499
13.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Lancet Oncol;
17(6): 791-800, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27179402
14.
First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial.
Clin Lung Cancer;
17(2): 150-60, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26809984
15.
First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study.
J Thorac Oncol;
11(3): 370-9, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26725183
16.
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned.
Cancer Res Treat;
47(4): 549-54, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25943319
17.
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.
Lancet Oncol;
16(5): 550-60, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25882987
18.
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.
Clin Cancer Res;
21(14): 3196-203, 2015 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25829397
19.
BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase.
Breast Cancer (Dove Med Press);
6: 179-89, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25473312
20.
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.
J Clin Oncol;
32(25): 2765-72, 2014 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25049330